Nicotinic Receptor Augmentation of SSRI Antidepressants
Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the nicotinic receptor antagonist
mecamylamine hydrochloride (Inversine) can augment SSRI-refractory major depression symptoms,
quality of life and cigarette smoking outcomes. A total of n=60 SSRI-refractory patients who
are on stable doses of an SSRI are being recruited into this 8-week double-blind, randomized,
placebo-controlled trial.